Engineering advancements in T cell manufacturing can lead to reduced associated production costs for CAR T cell therapies, enabling broader access and scalability for patient benefit.
Engineering advancements in T cell manufacturing can lead to reduced associated production costs for CAR T cell therapies, enabling broader access and scalability for patient benefit.